

Curriculum Vitae

Personal information Rosanna Botta

Work experience

- 1. Senior Researcher
 - Start date: 2022
 - Current
 - Istituto Superiore di Sanità National Center for National Center for Drug Research and Evaluation
 - City: Rome Country: Italy
 - Main activities held:
 - Quality and Non-Clinical assessment of Clinical Trial Applications with ATMPs and Biological Medicinal Products (Reg. 536-2014).
 Italian Delegate of CTP (Cell Therapy Products) working group of the European
 - Pharmacopoeia, Strasbourg, France
 - Assessment of non-clinical studies and of the 3R compliance according to Dir 2010/63/UE
 - (Italian Minister of Health)
 GLP Inspections (Italian Minister of Health) OCSE area of expertise: ATMP Pharmacodynamics, Pharmacological Toxicity, Safety studies

Partecipation in GMP Inspection as an ATMP Expert

2. Researcher

- End date: 2021
- Istituto Superiore di Sanità National Center for National Center for Drug Research and Evaluation
- City: Rome Country: Italy Main activities held:
- Quality and Non clinical assessment of Phase-I clinical studies involving ATMP National and EMA Scientific Advices
- Training courses and Masters on regulatory affairs of ATMP
- Research activities on Cell Therapy: in vitro and in vivo models for Stem Cell research.

 Xenograft experiments in immunodeficient mice
- Experimental Hematology and in vitro Stem Cell Biology studies
 Research Associate

- Start date: 2002 End date: 2004
- Thomas Jefferson University, Kimmel Cancer Institute
- City: Philadelphia Country: United States Main activities held:
- Research projects on Normal and Neoplastic Hematopoiesis
- Gene transfer in hematopoietic stem cells using viral and non viral vectors
- In vivo models for Stem Cell Research: xenograft experiments with genetically modified human hematopoietic stem cells

- Translational research. Study of stem cell plasticity in a model of heart infarct
- NOD SCID Mouse colony generation and maintenance

4. Researcher

- Start date: 2001
- End date: 2006
- Listituto Superiore di Sanità Hematology and Oncology Department City: Rome Country: Italy Main activities held:

- Planning and execution of research projects on Experimental Hematology and Cell biology Study of normal and neoplastic stem cells properties and regenerating/differentiating activity
- In vivo models for studying stem cell plasticity and ectopic stem cells differentiation Principal Investigator of research projects on stem cell research
- Supervisor of the xenograft experiments performed at the SPF Animal Facility San Raffaele South Park of Castel Romano, Rome

Education and training

- 1. Master's Degree
 - Start date: 2010
 - End date: 2011

 - Organisation: University La Sapienza, Rome, Italy
 Regulatory affairs on Pharmaceutical products for human use: manufacturing and quality of biological medicinal products and advanced therapies, clinical trial authorization and AIC
- 2. Visiting Scientist
 - Start date: 2000

 - End date: 2002 Organisation: Thomas Jefferson University Kimmel Cancer Institute, Philadelphia
 - In vivo HSC repopulating assays. Ectopic gene transfer: the role of tyrosine kinase receptors in stem cell activity
- 3. Scolarship on Cancer Research (Italian Association for Cancer Research)

- Start date: 1996
- End date: 1998
- Organisation: Istituto Superiore di Sanità Hematology/Oncology Department City: Rome, Country: Italy
- Studies on hematopoietic stem cell activity by in vitro models
- The role of TAL 1 gene in normal and neoplastic hematopoiesis
- 4. Internship on Clinical Hematology and Microbiology
 - Start date: 1994 End date: 1995

 - Organisation: Hematology and Microbiology Department Ospedale Generale Provinciale City: Rieti, Country: Italy Diagnostic methodologies in hematological, immunological and microbiological field
- 5. Certification of Biologist (DPR n.980/1982)Start date: 1995
- Organisation: University of Rome Tor Vergata
 City: Rome, Country: Italy
 Degree in Biological Sciences with honors
- - Start date: 1993 Organisation: University of Rome Tor Vergata
 - City: Rome, Country: Italy

Additional information

Publications

- Bellino S, La Salvia A, Cometa MF, Botta R. Cell-based medicinal products approved in the European
- Bellino S, La Salvia A, Cometa MF, Botta R. Cell-based medicinal products approved in the European Union: current evidences and perspectives. Front Pharmacol. 2023 Jul 31;14:1200808.

 R. Botta and G. Migliaccio: Cell_based Treatments: Advanced Therapies and Transplants. Transplantation Proceedings, 2011 Jan_Feb; 43(1):338_40C.Carella, F.Capone, R. Botta e G.Migliaccio. European regulations of MSC for clinical use. Regenerative Medicine and Cell Therapy. Biomedical and Health Research, Nov 2012, Vol.77

 N. Felli, L. Fontana, E. Pelosi, R. Botta, et al. (2005). MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via Kit recentor downmodulation PNAS. Dec 13:102(50):18081.6 Epub
- and erythroleukemic cell growth via Kit receptor downmodulation.PNAS Dec 13;102(50):18081 6.Epub
- R. Botta et al, (2004). Heart Infarct in NOD_SCID mice: Therapeutic vasculogenesis by transplantation of human CD34+ cells and low dose CD34+KDR+ cells. FASEB J. Sep;18(12):1392
- E. Pelosi, M. Valtieri, S. Coppola, R. Botta, et al. (2002). Identification of the hemangioblast in postnatal life. Blood. 100 (9) 3203_3208

- life. Blood. 100 (9) 3203_3208

 Peschle C., Botta R., Muller R., Valtieri M., and Ziegler B.L.(2001) Purification and functional assay of pluripotent hematopoietic stem cells. Reviews in Clinical and Experimental Hematology. 5(1):3_14

 R.Botta, M.Valtieri, R.Muller, D.Brambilla, B.Masella, G.Marziali, A, Eramo, L.Luchetti, B.Ziegler, C.Peschle (2000). Dedifferentiation of CD34+KDR_ progenitors by FLK1 gene transfer _ Suppression of clonogenic activity and rescue of engrafting capacity. Experimental Hematology 01/2000; 28(12)

 Grignani F, Valtieri M., Gabbianelli M., Gelmetti V., Botta R., Luchetti L., Masella B., Morsilli O., Pelosi E., Samoggia P., Pelicci PG., Peschle C. (2000) PML/RAR alpha fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype. Blood. 96(4): 1531 7
- 1531_/
 Valtieri M., Tocci A., Gabbianelli M., Luchetti L., Masella B., Botta R., Testa U., Condorelli G.L., and Peschle C. (1998). Enforced TAL_1 expression stimulates primitive, erythroid and megakaryocytic progenitors but blocks the granulopoietic differentiation program. Cancer Res. 58:562_569
 Condorelli G.L., Tocci A., Botta R., Facchiano F., Testa U., Vitelli L., Valtieri M., Croce C.M., and Peschle C. (1997). Ectopic TAL_1/SCL expression in phenotypically normal or leukemic myeloid precursors: proliferative and antiapoptotic effects coupled with differentiation blockade. Mol. Cell. Biol. 17: 2954_2969
- Botta R., and Gustavino B. (1997). Relationship between chromatin bridges in anaphase and chromosomal aberrations induced by TMP + UVA (365 nm) in CHO cells. Mutat. Res. 374: 253_259

 F Capone, C. Carella, R.Botta, G. Migliaccio. Cellule staminali da cordone ombelicale. Donazione o uso
- proprio? Avvenire medico. Aprile 2010; 27_28 Rosanna Botta, Maria Elena Fabucci, Giovanni Migliaccio. Staminali: mercato e sogni. Rivista sulla
- sicurezza sanitaria. Agosto_Ottobre 2007

Projects

- •2005: Principal Investigator of the project: Innovative strategies for regenerative therapies based on the use of stem cells. National Institute of Health _ Italy
- •2003 2005: Co Investigator of the project: Ischemic cardiovascular and degenerative diseases study of mechanisms of differentiation and therapeutic application of post_natal hematopoietic stem cells. National Program on Stem Cells, Italy.
- •2003: Principal Investigator of the project: In vivo repopulating assays for hematopoietic stem cells. National Institute of Health _ Italy
- •1999: Principal Investigator of the project: TAL_1_induced leukemogenesis: Identification and mechanism of action of the target genes of TAL_1 ectopically expressed. Italian Foundation for Cancer Research _ FIRC.
- •1996_98 Principal Investigator of the project: Gene transfer of hematopoietic stem cells in oncology". Italian Association for Cancer Research _ AIRC.

Memberships

Other Relevant Information